

5 December, 2011

Eisai Co., Ltd.

## **STATEMENT: FARLETUZUMAB AND THE FAR 122 STUDY**

Morphotek, a subsidiary of Eisai Inc., has decided to terminate FAR122 (MORAb-003-003), a study of its investigational agent farletuzumab, in platinum-resistant ovarian cancer. This decision was based on the results of an interim analysis conducted by an Independent Data Monitoring Committee (IDMC) that determined the study was unlikely to meet its statistically defined endpoints of progression-free survival and overall survival. Morphotek has notified investigators of this discontinuation.

Neither Morphotek nor the IDMC has identified any safety issues that impact this decision.

Platinum-resistant ovarian cancer refers to a late stage of ovarian cancer which no longer responds to platinum containing chemotherapy and has an extremely poor prognosis

The Phase III study (FAR131, MORAb-003-004) with farletuzumab in patients with platinum-sensitive ovarian cancer is still ongoing and currently recruiting. For more information, visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

\*\*\* ENDS \*\*\*